WENA (Anew Medical Inc.) יחס שווי שוק לשווי בספרים

Anew Medical, Inc. (WENA) developments against neurodegeneration are completely independent of macroeconomic cycles and seasonality. The P/BV ratio history visualizes this resilience, where -7.32 indicates the current level of the metric. Anew Medical, Inc. (WENA) minimizes risks through gene therapy for Alzheimer's and Parkinson's diseases, maintaining high operational readiness across its R&D laboratories and partner production lines.

This ratio compares the market value of the business to the value of its net assets, demonstrating the extent to which capital is overvalued or undervalued relative to tangible assets. By analyzing the current trend of the market-to-book multiple, an investor assesses whether the market premium is justified. For Anew Medical, Inc. (WENA), the absence of debt minimizes financial risks, while a patent portfolio of biotechnological developments creates a fundamental base for sustaining asset value.